White N J, Looareesuwan S, Edwards G, Phillips R E, Karbwang J, Nicholl D D, Bunch C, Warrell D A
Br J Clin Pharmacol. 1987 Feb;23(2):127-35. doi: 10.1111/j.1365-2125.1987.tb03020.x.
Amodiaquine hydrochloride (3 mg base kg-1) was given by constant rate intravenous injection over 10 min to seven healthy adult male volunteers, and by constant rate infusion (10 mg base kg-1) over 4 h to 10 adult patients admitted to hospital with falciparum malaria. After intravenous injection in volunteers there was considerable variation in plasma concentration profiles between subjects; peak plasma concentrations ranged between 65 and 1921 ng ml-1. A biexponential equation was fitted to the plasma concentration time data and the following estimated pharmacokinetic parameters (geometric mean; range) were derived; lambda 1 = 24.4 (7.6-95.0) h-1, lambda 2 = 0.33 (0.12-0.79) h-1, V1:1.1 (0.3-3.6) 1 kg-1, Vss: 17.4 (2.3-95.9) 1 kg-1 and systemic clearance 13.0 (4.7-56.6) 1 kg-1 h-1. After intravenous infusion there was also considerable variability between patients with post-infusion plasma concentrations ranging between 82 and 836 ng ml-1. The plasma concentration-time profiles were biphasic with the following estimated pharmacokinetic parameters (geometric mean; range) alpha = 1.87 (0.60-8.52) h-1, beta = 0.069 (0.021-0.265) h-1, V1: 4.6 (0.5-29.3) 1 kg-1, Vss: 38.3 (3.7-127.9) 1 kg-1 and systemic clearance CL (1.6-17.3) 1 kg-1 h-1. There was no measurable long terminal elimination phase, and the principal metabolite desethyl amodiaquine was not detected in the plasma samples. There was no serious toxicity in either group. During intravenous injection there was a significant fall in systolic blood pressure in four subjects (mean fall 16 mm Hg) but there was no significant change in heart rate.(ABSTRACT TRUNCATED AT 250 WORDS)
对7名健康成年男性志愿者,以每10分钟静脉恒速注射盐酸氨酚喹(3毫克碱基/千克);对10名因恶性疟入住医院的成年患者,以每4小时静脉恒速输注(10毫克碱基/千克)。志愿者静脉注射后,受试者间血浆浓度曲线差异很大;血浆峰值浓度在65至1921纳克/毫升之间。对血浆浓度-时间数据拟合双指数方程,得出以下估计的药代动力学参数(几何均值;范围):λ1 = 24.4(7.6 - 95.0)小时-1,λ2 = 0.33(0.12 - 0.79)小时-1,V1:1.1(0.3 - 3.6)升/千克,Vss:17.4(2.3 - 95.9)升/千克,全身清除率13.0(4.7 - 56.6)升/千克·小时-1。静脉输注后,患者间也存在很大变异性,输注后血浆浓度在82至836纳克/毫升之间。血浆浓度-时间曲线呈双相,以下是估计的药代动力学参数(几何均值;范围):α = 1.87(0.60 - 8.52)小时-1,β = 0.069(0.021 - 0.265)小时-1,V1:4.6(0.5 - 29.3)升/千克,Vss:38.3(3.7 - 127.9)升/千克,全身清除率CL(1.6 - 17.3)升/千克·小时-1。未观察到可测量的长终末消除相,血浆样本中未检测到主要代谢物去乙基氨酚喹。两组均未出现严重毒性。静脉注射期间,4名受试者收缩压显著下降(平均下降16毫米汞柱),但心率无显著变化。(摘要截断于250字)